-

06:51:57 PM

DYAI Stock News

DYAI - Dyadic International Inc., DE

03/15/23 8:30 AM

Nasdaq : DYAI

conferencesearningslow float

Dyadic to Report 2022 Year End Financial Results on Wednesday, March 29, 2023

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet

RHEA-AI

neutral

03/07/23 8:30 AM

Nasdaq : DYAI

clinical trialcovid-19low float

Dyadic Provides Phase 1 Clinical Trial Update for its DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dyadic International, Inc. ("Dyadic", "we", "us",

RHEA-AI

neutral

03/01/23 8:30 AM

Nasdaq : DYAI

conferenceslow float

Dyadic to Present at Roth Investor Conference and Upcoming Industry Events

Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for

RHEA-AI

neutral

02/02/23 8:30 AM

Nasdaq : DYAI

conferenceslow float

Dyadic to Participate in Two Upcoming Investor Conferences

Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for

RHEA-AI

neutral

01/24/23 8:30 AM

Nasdaq : DYAI

clinical trialcovid-19low float

Dyadic Announces Initiation of Dosing of First-In-Human Phase 1 Trial to Demonstrate Clinical Safety and Antibody Response in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate

Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial protein production platforms today announced that, in line with the timing announced

RHEA-AI

neutral

01/19/23 8:30 AM

Nasdaq : DYAI

low float

Dyadic Announces Sale of Equity Interest in Alphazyme

Dyadic International, Inc. ("Dyadic", or the "Company") (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for

RHEA-AI

neutral

01/04/23 8:30 AM

Nasdaq : DYAI

conferenceslow float

Dyadic to Attend J.P. Morgan 41st Annual Healthcare Conference

Dyadic International, Inc. (“Dyadic”, or the

RHEA-AI

neutral

12/14/22 8:30 AM

Nasdaq : DYAI

covid-19low float

Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal

“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s anticipated First-In-Human clinical trial designed to demonstrate clinical safety and immune response

RHEA-AI

neutral

11/10/22 4:00 PM

Nasdaq : DYAI

earningslow float

Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments

Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidate Presented safety, efficacy, and

RHEA-AI

positive

11/07/22 8:30 AM

Nasdaq : DYAI

conferenceslow float

Dyadic to Present at Upcoming Industry and Investor Events in November

Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for

RHEA-AI

neutral

1 2 3 4 5 6 7 Next

DYAI Data

IndustryAll Other Basic Organic Chemical Manufacturing
Websitewww.dyadic.com
Security nameDyadic International Inc., DE
Issue typecs
SectorManufacturing
Sic code2869
Employees7
Tags
- Biotechnology
- Health Technology
- Manufacturing
- All Other Basic Organic Chemical Manufacturing

About Dyadic International Inc., DE

Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical gene expression platform based on the fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila), named C1. The C1 microorganism, which enables the development and large-scale manufacture of low-cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles (VLPs) and antigens, monoclonal antibodies, Fab antibody fragments, Fc-Fusion proteins, biosimilars and/or biobetters, and other therapeutic proteins. Certain other research activities are ongoing which include the exploration of using C1 to develop and produce certain metabolites and other biologic products. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in development and manufacture of biopharmaceuticals. As the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic vaccines, drugs, and other biologic products to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers, and improve access and cost to patients and the healthcare system, but most importantly save lives.